5-amino-1-methyl-2(1H)-pyridinone oxalate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-amino-1-methyl-2(1H)-pyridinone oxalate
• 英文别名: 5-amino-1-methyl-2(1H)-pyridone oxalate；5-amino-1-methylpyridin-2-one;oxalic acid
• 化学式: C₂H₂O₄*C₆H₈N₂O
• 分子量: 214.178
• InChiKey: BBBSPXBKMZHOHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.88
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-bromo-2,7-bis(trifluoromethyl)quinoline 、 5-amino-1-methyl-2(1H)-pyridinone oxalate 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium phosphate 、 Pd2dba3*CH2Cl2 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以26%的产率得到4-[(1-methyl-pyridin-5-yl-2-one)amino]-2,7-bis(trifluoromethyl)quinoline
  参考文献：
  名称：

  Identification of 5-(Aryl/Heteroaryl)amino-4-quinolones as Potent Membrane-Disrupting Agents to Combat Antibiotic-Resistant Gram-Positive Bacteria

  摘要：

  Nosocomial infections caused by resistant Gram-positive organisms are on the rise, presumably due to a combination of factors including prolonged hospital exposure, increased use of invasive procedures, and pervasive antibiotic therapy. Although antibiotic stewardship and infection control measures are helpful, newer agents against multidrug-resistant (MDR) Gram-positive bacteria are urgently needed. Here, we describe our efforts that led to the identification of 5-amino-4-quinolone 111 with exceptionally potent Gram-positive activity with minimum inhibitory concentrations (MICs) ≤0.06 μg/mL against numerous clinical isolates. Preliminary mechanism of action and resistance studies demonstrate that the 5-amino-4-quinolones are bacteriostatic, do not select for resistance, and selectively disrupt bacterial membranes. While the precise molecular mechanism has not been elucidated, the lead compound is nontoxic displaying a therapeutic index greater than 500, is devoid of hemolytic activity, and has attractive physicochemical properties (clog P = 3.8, molecular weight (MW) = 441) that warrant further investigation of this promising antibacterial scaffold for the treatment of Gram-positive infections.

  DOI：

  10.1021/acs.jmedchem.2c01151
• 作为产物：
  描述：

  1-甲基-5-硝基-2(1H)-吡啶酮 在 Pd-C 氢气 、 草酸 作用下， 以 乙醇 为溶剂， 以52.6%的产率得到5-amino-1-methyl-2(1H)-pyridinone oxalate
  参考文献：
  名称：

  FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS

  摘要：

  公开号：

  EP1221444B1

文献信息

• Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease
  申请人：BLANK Jutta

  公开号：US20140349990A1

  公开（公告）日：2014-11-27

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物的公式(I)或其药用盐；制备本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。
• [EN] PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] NOUVEAUX DÉRIVÉS PYRAZOLOPYRROLIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：NOVARTIS AG

  公开号：WO2014191896A1

  公开（公告）日：2014-12-04

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物的公式(I)或其药学上可接受的盐；制备本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和药物组合物。
• Pyrazolopyrrolidine derivatives and their use in the treatment of disease
  申请人：Bordas Vincent

  公开号：US08975417B2

  公开（公告）日：2015-03-10

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式（I）的化合物或其药学上可接受的盐；制造本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。
• PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
  申请人：BLANK Jutta

  公开号：US20160095843A1

  公开（公告）日：2016-04-07

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式（I）的化合物或其药学上可接受的盐，制备该发明化合物的方法以及其治疗用途。本发明还提供了一种药理活性剂的组合和一种药物组合物。
• US8975417B2
  申请人：——

  公开号：US8975417B2

  公开（公告）日：2015-03-10